Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004
A case report: surprising diagnosis of malignant mesothelioma in a patient with malignant pleural effusion, mediastinal lymphoma and intestinal carcinoma in situ Source: Eur Respir J 2004; 24: Suppl. 48, 527s Year: 2004
Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Different prevalence of positivity for human mammaglobin (hMAM) transcipts in the pleural fluid of patients with malignant vs. non malignant pleural disease Source: Eur Respir J 2006; 28: Suppl. 50, 580s Year: 2006
Pleural atypical mesothelial hyperplasia: An early stage of pleural malignant mesothelioma? Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012
The value of IL6 in differentiation between malignant and non malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010
Diagnostic value of Ki-67 and repp 86 in distinction between benign and malignant mesothelial proliferations Source: Eur Respir J 2006; 28: Suppl. 50, 784s Year: 2006
An update on treatment of malignant pleural effusion with or without known primary bronchial adenocarcinoma Source: Annual Congress 2006 - Medical and surgical management of malignant pleuritis Year: 2006
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
The role of thoracoscopy in the diagnosis of malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Malignant pleural effusion cells show aberrant glucose metabolism gene expression Source: Eur Respir J 2011; 37: 1453-1465 Year: 2011
The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Timp-2 expression in the cytologic evaluation of adenocarcinoma pleural effusions Source: Annual Congress 2007 - Pleural malignancy Year: 2007
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004